Clayface Reviews: DC’s Body-Horror Gamble Splits Critics Ahead of October
- The Scoop: DC Studios’ Clayface, directed by James Watkins and starring Tom Rhys Harries, opens in U.S. theaters on October 23, 2026, and early reviews are sharply divided.
- Tone & Execution: Critics describe a gory body-horror origin story built around Matt Hagen’s disfigurement and radical facial treatment, not a conventional superhero tentpole.
- Studio Stakes: Positioned as a lower-profile entry in James Gunn and Peter Safran’s early DCU slate, the film is not expected to match Superman‘s $619 million worldwide haul.
Clayface lands in U.S. theaters on October 23, 2026, and the first wave of reviews is split clean down the middle: USA Today branded it a “messy DC miss” at two out of four stars.
The DC Studios body-horror experiment, directed by James Watkins and led by Tom Rhys Harries as Matt Hagen, is drawing praise for its gore and its lead performance while taking fire for a predictable story.
Body Horror Over Capes: Watkins Stages a Villain Origin With Teeth
Watkins builds the film around Hagen’s disfigurement at the hands of a mob boss, played by Eddie Marsan, then tracks his spiral through radical facial treatment into the Clayface mutation.
The result is a revenge narrative fused with a tragic transformation, an edgy, violent standalone villain story rather than a franchise-building spectacle. ScreenDaily praised the gore and the central performance while faulting underdeveloped characters.
TheWrap landed in similar territory, calling it an effective but “hardly brilliant” gross-out horror film. That split verdict matters for a project selling itself on physical transformation over CGI spectacle.
Harries anchors the film as a relatively unknown lead opposite Naomi Ackie, David Dencik, and Max Minghella, a casting bet that puts performance pressure squarely on an untested name. The ensemble’s depth is doing the commercial heavy lifting here, echoing the kind of ensemble-driven horror bets monitored across our contemporary genre releases in this corridor.
DC’s October Gamble: A Low-Ceiling Bet in a High-Stakes Slate
Clayface sits in the early DCU film slate curated by James Gunn and Peter Safran, following Superman and Supergirl. The screenplay comes from Mike Flanagan and Hossein Amini, a pairing that signals horror pedigree over superhero formula.
ScreenDaily reports the film is not expected to approach Superman‘s $619 million worldwide gross, a deliberate ceiling, not an accident. DC wants this lower-profile project to succeed on its own terms.
The October 23 date plants the film squarely in the Halloween-season theatrical corridor, a window that rewards violent, adult-skewing horror. Distributors get a genre-aligned weekend with minimal superhero competition.
For DC Studios, the math is straightforward: a contained production with a modest ceiling either validates the studio’s appetite for risk or exposes how thin its bench is beyond flagship characters. Either outcome gets tracked across our trade entertainment desk as the October corridor takes shape.
The critical split is the real variable. A “hardly brilliant” gross-out horror film can still convert Halloween-season foot traffic, but only if audiences show up for the transformation, not the cape.